Tyler Van Buren
Stock Analyst at TD Cowen
(1.79)
# 3,315
Out of 5,048 analysts
58
Total ratings
42.55%
Success rate
-0.17%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $34.53 | +15.84% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $61.98 | +53.28% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $122.05 | +2.42% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $31.36 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $41.90 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $15.22 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $14.85 | +405.05% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $16.00 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $26.18 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $24.91 | +140.87% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.77 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $8.13 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $642.25 | +86.84% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $17.51 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $37.01 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $61.97 | -51.59% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.78 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $86.13 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.35 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.26 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $32.38 | +116.18% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.44 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.72 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.43 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $12.35 | +1,721.86% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $7.53 | +11,520.19% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $12.62 | +216.96% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $15.22 | +97.11% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.42 | +14,219.81% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.67 | +2,894.01% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.39 | +1,155.23% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $4.29 | +4,562.00% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.17 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.52 | - | 1 | Aug 4, 2017 |
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $34.53
Upside: +15.84%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $61.98
Upside: +53.28%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $122.05
Upside: +2.42%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $31.36
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $41.90
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $15.22
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $14.85
Upside: +405.05%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $16.00
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $26.18
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $24.91
Upside: +140.87%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $3.77
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $8.13
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $642.25
Upside: +86.84%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $17.51
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $37.01
Upside: -
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $61.97
Upside: -51.59%
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $23.78
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $86.13
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $54.35
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.26
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $32.38
Upside: +116.18%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.44
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.72
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $15.43
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $12.35
Upside: +1,721.86%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $7.53
Upside: +11,520.19%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $12.62
Upside: +216.96%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $15.22
Upside: +97.11%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.42
Upside: +14,219.81%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.67
Upside: +2,894.01%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $2.39
Upside: +1,155.23%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $4.29
Upside: +4,562.00%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $7.17
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $20.52
Upside: -